ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Melbye, H
Right arrow Articles by Vorland, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Melbye, H
Right arrow Articles by Vorland, L
Eur Respir J 1994; 7: 1239-1245
Copyright © ERS Journals Ltd 1994

Original Articles

Reversible airflow limitation in adults with respiratory infection

H Melbye, J Kongerud, and L Vorland

The aim of the study was to determine the occurrence of airflow limitation and the frequency of significant reversibility in respiratory infections in adults without known asthma or chronic obstructive pulmonary disease (COPD). We also wanted to study the association between airflow limitation and aetiological agents diagnosed by serological analyses. Spirometry was performed in 574 adult general practice patients with upper or lower respiratory tract infection, and follow-up measurement was obtained in 429 of them. In the latter group, we also obtained paired sera for analysis of anti-bodies against respiratory viruses, chlamydial and mycoplasmal agents. Median forced expiratory volume in one second (FEV1) in all patients included was 90% of predicted; significantly lower in patients with an established diagnosis of asthma or COPD, compared to those without, 77 and 91% predicted, respectively. Among the patients without known asthma or COPD there was a strong association between low FEV1 and the symptoms cough and dyspnoea. Both acute-phase and follow-up FEV1 was measured in 395 of the patients without known asthma or COPD, and a significant increase in median value from 92 to 96% was registered. A reversibility of FEV1 of > 15% was measured in 23% of the 395 patients, uninfluenced by anti-asthma treatment in the great majority. Patients with an established viral, mycoplasmal or chlamydial infection had a significantly lower FEV1 at entry and a greater reversibility, compared to those without such aetiological diagnosis. We conclude that reversible obstruction was particularly common in the patients diagnosed as having acute bronchitis, but that it was found in the patients patients diagnosed as having upper respiratory tract infection.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 ChestHome page
S. S. Braman
Chronic Cough Due to Acute Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines
Chest, January 1, 2006; 129(1_suppl): 95S - 103S.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. Gonzales
A 65-Year-Old Woman With Acute Cough Illness and an Important Engagement
JAMA, May 28, 2003; 289(20): 2701 - 2708.
[Full Text] [PDF]

Home page
 ThoraxHome page
A J White, S Gompertz, and R A Stockley
Chronic obstructive pulmonary disease * 6: The aetiology of exacerbations of chronic obstructive pulmonary disease
Thorax, January 1, 2003; 58(1): 73 - 80.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Kraft, G. H. Cassell, J. Pak, and R. J. Martin
Mycoplasma pneumoniae and Chlamydia pneumoniae in Asthma* : Effect of Clarithromycin
Chest, June 1, 2002; 121(6): 1782 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Chiba, S. Pattanajitvilai, A. J. Evans, R. J. Harbeck, and D. R. Voelker
Human Surfactant Protein D (SP-D) Binds Mycoplasma pneumoniae by High Affinity Interactions with Lipids
J. Biol. Chem., May 31, 2002; 277(23): 20379 - 20385.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Gonzales, J. G. Bartlett, R. E. Besser, R. J. Cooper, J. M. Hickner, J. R. Hoffman, and M. A. Sande
Principles of Appropriate Antibiotic Use for Treatment of Uncomplicated Acute Bronchitis: Background
Ann Intern Med, March 20, 2001; 134(6): 521 - 529.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J Macfarlane, W Holmes, P Gard, R Macfarlane, D Rose, V Weston, M Leinonen, P Saikku, and S Myint
Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community
Thorax, February 1, 2001; 56(2): 109 - 114.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
R. Gonzales and M. A. Sande
Uncomplicated Acute Bronchitis
Ann Intern Med, December 19, 2000; 133(12): 981 - 991.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Hickman-Davis, J. Gibbs-Erwin, J. R. Lindsey, and S. Matalon
Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite
PNAS, April 27, 1999; 96(9): 4953 - 4958.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. C. Cartner, J. R. Lindsey, J. Gibbs-Erwin, G. H. Cassell, and J. W. Simecka
Roles of Innate and Adaptive Immunity in Respiratory Mycoplasmosis
Infect. Immun., August 1, 1998; 66(8): 3485 - 3491.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. M. Hickman-Davis, J. R. Lindsey, S. Zhu, and S. Matalon
Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages
Am J Physiol Lung Cell Mol Physiol, February 1, 1998; 274(2): L270 - L277.
[Abstract] [Full Text] [PDF]

Home page
 Arch Fam MedHome page
H. A. Williamson Jr
Treatment of Acute Bronchitis: There's Much Work to Be Done
Arch Fam Med, February 1, 1996; 5(2): 84 - 85.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the European Respiratory Society.